Home HLA and Immune Genetics Familial Mediterranean Fever Genetic Test: MEFV Gene, Inflammation, and Results

Familial Mediterranean Fever Genetic Test: MEFV Gene, Inflammation, and Results

By
Vita Library
-
2
Learn how MEFV testing supports familial Mediterranean fever diagnosis, including variants, carrier results, colchicine treatment, and amyloidosis risk.

A familial Mediterranean fever genetic test looks for variants in the MEFV gene, which provides instructions for making pyrin, a protein that helps regulate innate immune inflammation. Familial Mediterranean fever, or FMF, causes repeated attacks of fever and painful inflammation, often in the abdomen, chest, joints, or skin. Genetic testing can support the diagnosis, clarify inheritance, and help evaluate relatives, but it is not a simple yes-or-no test. Some people with classic symptoms have only one detectable MEFV variant or no clearly pathogenic variant, while many healthy people carry a common variant and never develop disease. Results must therefore be interpreted with the attack pattern, ancestry, inflammatory markers, family history, and response to colchicine. Early recognition matters because ongoing inflammation can lead to AA amyloidosis, especially kidney damage from amyloid protein deposition. A specialist may use targeted variant testing, full MEFV sequencing, or a broader autoinflammatory disease panel depending on the presentation.

  • The test detects inherited MEFV variants associated with abnormal pyrin-driven inflammation.
  • Two pathogenic variants strongly support FMF, but one variant can still be clinically relevant.
  • A negative test does not completely exclude FMF when the symptoms are typical.
  • A variant of uncertain significance is not proof of disease and should not guide treatment alone.
  • Recurrent fever with severe abdominal or chest pain needs clinical assessment even before genetic results return.

Table of Contents

What Familial Mediterranean Fever Is

FMF is a hereditary autoinflammatory disease. Autoinflammatory disorders arise from inappropriate activation of the innate immune system, the body’s fast first-line defense. This differs from classic autoimmune disease, in which adaptive immune cells and autoantibodies target the body’s own tissues.

The MEFV gene encodes pyrin. Pyrin helps control an inflammatory protein complex called the pyrin inflammasome. Disease-associated variants can make this pathway easier to activate, leading to excess production of interleukin-1 and episodes of intense but self-limited inflammation.

Typical attacks begin abruptly and usually last 12 to 72 hours. Features can include:

  • Fever, often 38°C to 40°C (100.4°F to 104°F)
  • Severe abdominal pain from inflammation of the abdominal lining
  • Sharp chest pain that worsens with breathing
  • Pain and swelling in one or more large joints, commonly an ankle or knee
  • A red, warm, tender rash over the lower leg or ankle
  • Muscle pain, especially after exertion
  • Scrotal pain or swelling in some males

People are often well between attacks, although low-grade inflammation may continue. Symptoms commonly begin in childhood or adolescence, but adult-onset disease occurs. Attacks may follow stress, infection, menstruation, strenuous exercise, cold exposure, or missed colchicine doses, yet many episodes have no clear trigger.

FMF is most common among people with ancestry from the eastern Mediterranean, including Sephardic Jewish, Armenian, Turkish, Arab, North African, Greek, and Italian populations. It can occur in any ancestry, and relying too heavily on ethnicity can delay diagnosis.

The most serious long-term complication is AA amyloidosis. Persistent production of serum amyloid A can lead to amyloid deposits, especially in the kidneys. Protein in the urine may be the first sign. Untreated progression can cause nephrotic syndrome and kidney failure. Effective suppression of inflammation greatly lowers this risk.

Who Should Consider MEFV Testing

MEFV testing is most useful when symptoms suggest recurrent sterile inflammation rather than ordinary infection. A clinician may recommend testing for repeated short fever episodes accompanied by abdominal, chest, joint, or skin inflammation, particularly when episodes are similar each time and resolve between attacks.

Testing may also be appropriate when a person has:

  • A close relative with confirmed FMF or pathogenic MEFV variants
  • Unexplained recurrent serositis, meaning inflammation around the abdominal organs, lungs, or heart
  • Recurrent monoarthritis that resolves between episodes
  • Persistent elevation of C-reactive protein or serum amyloid A without another explanation
  • Unexplained proteinuria or AA amyloidosis
  • A partial or strong response to a monitored colchicine trial
  • An atypical periodic fever syndrome that needs distinction from other inherited conditions

Children with attacks may be evaluated by pediatric rheumatology. Adults may see rheumatology, clinical immunology, nephrology, or medical genetics depending on the dominant symptoms.

Testing is not usually helpful for a single isolated fever or nonspecific chronic pain without objective inflammation. It also should not replace urgent assessment for appendicitis, pneumonia, pulmonary embolism, septic arthritis, inflammatory bowel disease, or other serious conditions. FMF attacks can mimic emergencies, and a known genetic result does not make every new pain episode an FMF attack.

A person with unexplained AA amyloidosis may need MEFV analysis even without a clear history of classic attacks. Some people develop kidney complications with mild or unrecognized inflammatory episodes. Urine protein, serum creatinine, inflammatory markers, and family history help frame that evaluation.

When symptoms overlap with several periodic fever disorders, a multigene panel may be more efficient than MEFV-only testing. Such panels can include genes associated with tumor necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, cryopyrin-associated periodic syndromes, and other autoinflammatory conditions.

How MEFV Genetic Testing Is Done

Testing usually uses a blood sample or saliva sample. No fasting is required. The laboratory extracts DNA and examines the MEFV gene for sequence changes.

Several test designs are available:

Targeted common-variant testing

A targeted test checks a limited list of frequently observed MEFV variants, often including M694V, M680I, M694I, V726A, and E148Q. It can be fast and less expensive in populations where common variants account for many cases. Its main limitation is that it can miss rare variants outside the selected list.

Full-gene sequencing

Sequencing examines the coding regions of MEFV and nearby splice boundaries. It can identify common and rare single-letter changes and small insertions or deletions. Some laboratories also evaluate copy-number changes, although these are not a frequent cause of FMF.

Autoinflammatory disease panel

A broader panel tests MEFV together with other genes. This approach is useful when attacks are prolonged, include unusual rashes or eye findings, begin in infancy, follow vaccination, involve severe oral ulcers, or otherwise do not fit classic FMF.

Before testing, the clinician or genetic counselor should document the age at onset, attack duration, fever pattern, affected organs, laboratory inflammation during and between attacks, ancestry, family history, and treatment response. This clinical “phenotype” is essential for interpreting variants.

The laboratory classifies variants using evidence such as population frequency, published cases, functional studies, location in the protein, inheritance within families, and expert databases. Categories generally include pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. A genetic variant result should be interpreted using the laboratory’s current classification, because classifications can change as evidence grows.

Turnaround time ranges from several days for a targeted test to several weeks for sequencing or a panel. Insurance coverage and preauthorization vary. Genetic counseling can help explain potential results, family implications, privacy, and the possibility of incidental findings on broader panels.

Understanding Positive, Negative, and Uncertain Results

The result should state each variant, its classification, and whether one or two copies were found. The combination of variants often matters more than any isolated label.

Two pathogenic or likely pathogenic variants

Finding two disease-causing variants—one on each copy of MEFV—strongly supports FMF in a person with compatible symptoms. This pattern is called biallelic. The two variants may be identical, called homozygous, or different, called compound heterozygous.

The phase of two variants may need confirmation. “In trans” means the variants are on opposite gene copies, one inherited from each parent. “In cis” means both are on the same copy. Testing parents or other relatives can sometimes establish phase.

Certain genotypes are associated on average with more severe disease. Homozygous M694V, for example, is often linked to earlier onset, more attacks, and greater amyloidosis risk. These are group-level associations, not exact predictions. Treatment and monitoring should follow the individual’s inflammation and clinical course.

One pathogenic or likely pathogenic variant

A single MEFV variant is a common and challenging result. FMF has traditionally been described as autosomal recessive, yet many clinically diagnosed patients have only one identified pathogenic variant. Several explanations are possible:

  • A second variant exists but the test did not detect it.
  • The identified variant has a dominant or dose-dependent effect in that person.
  • Other genetic and environmental factors modify inflammation.
  • The person is a carrier and the symptoms have another cause.

One variant can support the diagnosis when attacks are typical and other causes have been evaluated, but it does not establish FMF on its own. The exact variant matters. M694V generally carries different evidence from low-penetrance or debated variants.

Variant of uncertain significance

A VUS means the laboratory cannot determine whether the change causes disease. It is not a positive diagnosis. A VUS should not be used alone to label relatives, predict severity, or start lifelong treatment.

Interpretation may improve through family testing, ancestry-specific frequency data, functional studies, or later reclassification. The ordering clinician should periodically check whether the laboratory has updated the variant.

Negative result

A negative test means no reportable disease-causing MEFV variant was identified by that method. It does not completely exclude FMF. Targeted tests can miss rare variants, sequencing may not detect certain regulatory or structural changes, and some clinically definite cases remain genetically unresolved.

A negative result should prompt a review of the exact assay. If only common variants were tested, full sequencing or a broader panel may be reasonable. If comprehensive testing was negative, the clinician should reconsider other autoinflammatory, autoimmune, infectious, gastrointestinal, and hematologic causes.

Benign or likely benign variants

Benign variants are not considered a cause of FMF. They may still appear on raw reports or consumer tests, but they should not be treated as disease findings. E148Q deserves particular nuance because laboratories and experts have differed in classification and penetrance estimates. Its presence is most informative when considered with symptoms, ancestry, a second variant, and family data.

Inheritance, Carriers, and Family Risk

Classic FMF is usually inherited in an autosomal recessive pattern. Every person has two MEFV copies. A child with two disease-causing variants generally inherited one altered copy from each parent.

When both parents carry one pathogenic variant, each pregnancy has:

  • A 25% chance of a child inheriting both variants
  • A 50% chance of a child inheriting one variant and being a carrier
  • A 25% chance of a child inheriting neither familial variant

These probabilities reset with every pregnancy. They do not mean that exactly one of four children will be affected.

Inheritance is more complex than the simple model suggests. Some heterozygous people have FMF-like symptoms, while others remain healthy. Penetrance—the chance that a genotype produces symptoms—differs by variant and background. The same variant combination can cause severe childhood disease in one relative and milder adult disease in another.

Once familial variants are known, targeted testing can clarify whether siblings, adult children, or other relatives carry them. Testing an asymptomatic child should be discussed with genetics and pediatric specialists, particularly when the result could change monitoring or treatment. A carrier result does not necessarily require medicine, but relatives should know symptoms that warrant evaluation.

For a person with two confirmed variants, the chance of passing an altered copy to each child is essentially 100%; whether a child develops FMF depends on the other biological parent’s MEFV status and the specific variants. If the partner is not a carrier, children will usually be carriers rather than affected under the classic recessive model.

Reproductive options may include partner testing, prenatal diagnosis, or preimplantation genetic testing when the familial variants are established. These are personal choices. Genetic counseling can explain accuracy, limitations, timing, and ethical considerations without directing a particular decision.

An ancestry-based carrier estimate should not replace individual testing. MEFV carrier frequency is high in some populations, but mixed ancestry and population movement make assumptions unreliable.

How Results Fit the Diagnosis

FMF remains a clinical diagnosis supported by genetics. There is no single blood level, scan, or DNA finding that captures every case.

During an attack, C-reactive protein, erythrocyte sedimentation rate, white blood cell count, fibrinogen, and serum amyloid A often rise. These markers should fall as the attack resolves. Persistent elevation between attacks suggests subclinical inflammation and may increase amyloidosis risk.

Clinicians evaluate the attack pattern: abrupt onset, short duration, repeated similar episodes, objective fever, serositis, arthritis, erysipelas-like rash, symptom-free intervals, family history, and response to colchicine. Classification criteria can support consistency in research and practice, but they do not replace specialist judgment.

Conditions that may resemble FMF include:

  • PFAPA syndrome, especially in young children with mouth ulcers, sore throat, and swollen neck nodes
  • Tumor necrosis factor receptor-associated periodic syndrome, which often causes longer attacks
  • Mevalonate kinase deficiency, which may begin in infancy and follow vaccination
  • Cryopyrin-associated periodic syndromes, often with cold-triggered rash or hearing problems
  • Cyclic neutropenia
  • Systemic juvenile idiopathic arthritis or adult-onset Still disease
  • Lupus, vasculitis, inflammatory bowel disease, and Behçet disease
  • Recurrent infections, malignancy, porphyria, and other abdominal disorders

A monitored colchicine trial may support FMF when symptoms and inflammation clearly improve, but response is not fully specific. Colchicine can reduce inflammation in other conditions, and poor response may reflect an incorrect dose, missed doses, intolerance, or an alternative diagnosis.

Genetic testing is most persuasive when genotype and phenotype agree. Two well-established pathogenic variants plus classic attacks make the diagnosis highly likely. A VUS plus vague symptoms provides little certainty. A negative test plus classic recurrent serositis still deserves expert review rather than automatic dismissal.

Treatment, Monitoring, and Amyloidosis Prevention

Daily colchicine is the standard first-line treatment for most people with FMF. It reduces attacks and, even more importantly, prevents AA amyloidosis when taken consistently. It is preventive medicine, not only an attack treatment.

Dosing is individualized by age, body size, kidney and liver function, attack control, inflammation, side effects, and drug interactions. Common adverse effects include diarrhea, abdominal cramping, and nausea. Serious toxicity can cause muscle injury, low blood counts, neuropathy, or organ damage, especially with excessive doses, kidney impairment, or interacting medicines.

Strong inhibitors of CYP3A4 or P-glycoprotein can dangerously raise colchicine exposure. Examples include clarithromycin and certain antifungal, antiviral, and heart medications. Patients should have every new prescription checked for interactions and should never double doses after a missed tablet unless instructed.

Monitoring commonly includes:

  • Attack frequency, duration, and severity
  • C-reactive protein and serum amyloid A when available
  • Complete blood count
  • Kidney and liver function
  • Urinalysis and urine protein measurement
  • Growth and development in children
  • Adherence, side effects, and drug interactions

Protein in the urine requires prompt evaluation. It may signal AA amyloidosis, but diabetes, high blood pressure, infection, and other kidney diseases are also possible. Early nephrology involvement can help determine the cause.

A minority of patients have active disease despite the maximum tolerated colchicine dose or cannot tolerate the drug. Interleukin-1 inhibitors, including anakinra and canakinumab, can control colchicine-resistant FMF. Even when a biologic is added, colchicine is often continued if tolerated because of its established role in amyloidosis prevention.

Genotype may influence monitoring intensity but rarely determines treatment by itself. A high-risk genotype such as M694V homozygosity supports close surveillance, yet persistent inflammation and clinical attacks are the main treatment targets. Conversely, a person with a milder genotype still needs adequate therapy if inflammation is active.

Lifestyle steps cannot replace medication, but regular sleep, hydration, manageable exercise, and awareness of personal triggers may reduce disruption. A written plan can distinguish usual attacks from symptoms that need emergency care.

Next Steps After Testing

Review the complete laboratory report with a clinician familiar with autoinflammatory disease. Ask which method was used, which regions were examined, how each variant was classified, whether two variants are in trans, and whether the finding matches the symptoms.

For a positive or strongly supportive result, the next steps often include:

  1. Confirming the clinical diagnosis and documenting baseline attack frequency.
  2. Measuring inflammation, kidney function, and urine protein.
  3. Starting or optimizing colchicine under medical supervision.
  4. Reviewing interacting medicines and pregnancy considerations.
  5. Offering targeted testing or counseling to appropriate relatives.
  6. Establishing long-term rheumatology or immunology follow-up.

For one pathogenic variant, the clinician should assess how typical the attacks are and whether testing was comprehensive. Parental testing, full-gene analysis, or an autoinflammatory panel may add information. Treatment decisions should reflect the clinical syndrome rather than carrier status alone.

For a VUS, avoid testing healthy relatives indiscriminately unless genetics professionals believe segregation analysis could clarify the result. Keep a copy of the exact variant notation and laboratory name so reclassification can be checked later.

For a negative result, confirm whether the test was targeted or comprehensive. A negative common-variant panel may justify sequencing. A negative full panel may shift attention toward clinical diagnosis, repeated inflammatory measurements during attacks, and alternative disorders.

Seek urgent care for severe new abdominal pain, breathing difficulty, fainting, rigid abdomen, persistent vomiting, a hot swollen joint with fever, or symptoms unlike previous attacks. A diagnosis of FMF should not delay evaluation for infection or a surgical emergency.

Keep an attack diary with start and stop times, temperature, pain location, menstrual timing, triggers, missed doses, and laboratory results. Photographs of a rash or swollen joint can be useful. This record often reveals a pattern that is difficult to reconstruct from memory.

The most informative genetic result is one that is combined with observable inflammation and used to prevent complications. Regular colchicine, monitoring for silent inflammation, and early attention to urine protein can preserve long-term health even when the genotype is not perfectly straightforward.

Variant interpretation can change as laboratories collect more population and family data. A result that was once labeled uncertain may later be reclassified, particularly for uncommon MEFV variants or complex alleles. Keep the original laboratory name and report number, and ask whether the laboratory issues amended reports. Reanalysis is most useful when the phenotype remains convincing, relatives become available for testing, or newer sequencing can detect changes missed by an older assay. It should complement—not replace—review of attack pattern, inflammatory markers between attacks, response to colchicine, and alternative autoinflammatory diagnoses.

References

Disclaimer

This article provides general educational information and does not diagnose FMF or recommend an individual treatment plan. MEFV results should be interpreted by a qualified clinician using symptoms, inflammatory markers, family history, and the exact laboratory method. Severe or unusual pain, fever, breathing difficulty, or signs of kidney disease need prompt medical evaluation.

RELATED ARTICLESMORE FROM AUTHOR